Other Clinical Trial - CIDP07 Rozanolixizumab Post Trial Access Program

Updated 04/30/2024

Status No longer available

Clinical Trial Summary

This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Polyneuropathies
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Clinical Trial Details

NCT number	NCT05014724
Study type	Expanded Access
Source	UCB Pharma
Contact
Status	No longer available
Phase

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT06040567` - Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
	Active, not recruiting	`NCT04280718` - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)	Phase 2
	Recruiting	`NCT05492604` - Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP.	N/A
	Not yet recruiting	`NCT03166527` - Panzyga in CIDP Administered at Different Infusion Rates	Phase 3
	Completed	`NCT02027701` - Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Phase 3
	Completed	`NCT04281472` - A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)	Phase 2